MétaCan
Menu
Back to cohort
Record W4411294777 · doi:10.2337/db25-2003-lb

2003-LB: An mRNA Immunotherapy for Type 1 Diabetes

2025· article· en· W4411294777 on OpenAlexaffabout
Heather C. Denroche, Lindsay P. Pallo, Chen Sh, Volkova Ng, Josh Zaifman, MELISSA FERRAD, Yuen Yi C. Tam, C. Bruce Verchere

Bibliographic record

VenueDiabetes · 2025
Typearticle
Languageen
FieldMedicine
TopicHyperglycemia and glycemic control in critically ill and hospitalized patients
Canadian institutionsBurnaby Hospital
Fundersnot available
KeywordsImmunotherapyType 2 diabetesMedicineMessenger RNAImmunologyDiabetes mellitusInternal medicineBiologyEndocrinologyGeneticsImmune systemGene

Abstract

fetched live from OpenAlex

Introduction and Objective: Antigen-specific immune tolerance therapy (ASIT) is a potentially curative approach to type 1 diabetes (T1D) but has not translated successfully to the clinic. We developed a tolerogenic lipid nanoparticle (tLNP) to co-deliver immunomodulators and mRNA-encoded beta-cell autoantigens as a novel ASIT strategy for T1D and tested it for diabetes prevention and reversal in NOD mice. Methods: To assess whether tLNPs prevent diabetes, we injected NOD females biweekly from 5 to 15 weeks with tLNPs, control LNPs (antigen-only or irrelevant antigen with/without immunomodulators), or buffer, and monitored blood glucose to 30 weeks (diabetes onset = 2 readings > 20 mM). We compared administration routes in the NOD diabetes prevention model and performed immune profiling in blood and spleens by flow cytometry. To test reversal of new-onset diabetes, tLNPs were administered only after 2 consecutive blood glucose readings >13 mM, with monitoring 2x weekly up to 10 weeks post-onset (diabetes progression = 2 readings > 15 mM). Results: Treatment with tLNPs reduced diabetes incidence vs. buffer-injected controls (p=0.002). Protection was antigen-dependent, as irrelevant antigen with immunomodulators in LNPs was ineffective, similar to buffer control. Likewise, antigen-only LNPs were ineffective. Intramuscular (IM) was the most effective administration route, with 3x IM injections conferring 100% protection to 30 weeks. IM tLNP injection expanded circulating polyclonal and antigen-specific regulatory T cells and increased dysfunction markers in splenic CD4+ and CD8+ T effectors. Remarkably, tLNPs reversed new-onset diabetes in 100% of mice, with treated mice remaining euglycemic without supplemental insulin for the 10-week study (p=0.007 vs. buffer). Conclusion: TLNPs delivering mRNA-encoded antigens induce robust immune tolerance, preventing and reversing diabetes in NOD mice. This novel technology enables mRNA as a promising ASIT modality and warrants further preclinical development for T1D. Disclosure H.C. Denroche: Other Relationship; Integrated Nanotherapeutics. L.P. Pallo: None. S. Chen: Other Relationship; Integrated Nanotherapeutics. V. Ng: Employee; Integrated Nanotherapeutics. J. Zaifman: Other Relationship; Integrated Nanotherapeutics. M. Ferrad: Employee; Integrated Nanotherapeutics. Y. Tam: Other Relationship; Integrated Nanotherapeutics. B. Verchere: Board Member; Integrated Nanotherapeutics. Stock/Shareholder; Integrated Nanotherapeutics. Funding Breakthrough T1D (3-IND-2024-1575-I-X); Breakthrough T1D Canada (3-COE-2022-1103-M-B)

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.004
Threshold uncertainty score0.014

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0040.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.019
GPT teacher head0.315
Teacher spread0.297 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueDiabetesSame topicHyperglycemia and glycemic control in critically ill and hospitalized patientsFrench-language works237,207